Exhibit 99.1 Iridex Reports First Quarter 2024 Financial Results MOUNTAIN VIEW, Calif., May 14, 2024 -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights "We saw some of the firming we expected during the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdiction of in ...

IRIDEX Corporation (NASDAQ:IRIX) Q4 2023 Results Conference Call March 26, 2024 5:00 PM ET Company Participants Philip Taylor - IR David Bruce - CEO Fuad Ahmad - Interim CFO Conference Call Participants Tom Stephan - Stifel Operator Hello, and thank you for standing by. Welcome to IRIDEX Q4 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers’ presentation, there will be a question-and-answer session [Operator Instructions]. I would now like to hand the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27598 IRIDEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdict ...

IRIDEX Corporation (NASDAQ:IRIX) Q3 2023 Results Conference Call November 14, 2023 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer; Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital Operator Good day and thank you for standing by. Welcome to the Q3 2023 IRIDEX Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there ...

Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad - Interim Chief Financial Officer Operator Philip Taylor Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact, ...

As we look at the remainder of 2023, we expect to improve the growth rate of our glaucoma business and increase utilization. We are reiterating our guidance and continue to expect to sell 65,000 to 67,000 probes, representing growth of 9% to 12% compared to 2022. And expect to grow the G6 installed base by 225 to 250 systems. Fuad Ahmad Operating expenses for the first quarter were $8.3 million, flat compared to the same period last year. Our net loss in the quarter of -- first quarter of 2023 was $2.1 mill ...

Education and Training • Expanding peer-reviewed publications • Seminars/webinar/wetlabs • KOL support • IRIDEX-sponsored clinical trials • Social media outreach Product Enhancements 6 • Commercial rollout of enhanced probe tip • Technique and protocol simplification focus 11 S a l e s C yc l e : F o c u s i n g o n E x i s t i n g + N e w C u s t o m e rs GLAUCOMA SPECIALIST PHYSICIAN EDUCATION Validation Conversion Commitment to Benefits Targeting HANDS-ON TRAINING 12 Key Takeaways Significant market oppo ...

IRIDEX Corporation (NASDAQ:IRIX) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group David Bruce - President and CEO Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2022 IRIDEX Conference Call. At this time, all participants are in a listen-only mode. After the speakers' present ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) | Delaware | | | 77-0210467 | | --- | --- | --- | --- | | (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) | | | | | 1212 Terra Bella Avenu ...